This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1996 Nov;10(5):453-9.

doi: 10.2165/00019053-199610050-00002.

Treatment options in acromegaly. Benefits and costs

L M Weekes¹, K K Ho, J P Seale

Affiliations

PMID: 10163627
DOI: 10.2165/00019053-199610050-00002

Review

Treatment options in acromegaly. Benefits and costs

L M Weekes et al. Pharmacoeconomics. 1996 Nov.

. 1996 Nov;10(5):453-9.

doi: 10.2165/00019053-199610050-00002.

Authors

L M Weekes¹, K K Ho, J P Seale

Affiliation

¹ New South Wales Therapeutic Assessment Group Inc., Sydney, New South Wales, Australia.

PMID: 10163627
DOI: 10.2165/00019053-199610050-00002

No abstract available

PubMed Disclaimer

Similar articles

Cost-effectiveness of pharmacological treatment in vascular dementia.
Massoud F. Massoud F. Can J Neurol Sci. 2009 Nov;36(6):673-4. doi: 10.1017/s031716710000826x. Can J Neurol Sci. 2009. PMID: 19960742 No abstract available.
Cost-effectiveness of genotyping to guide treatment.
Sorich MJ, Wiese MD, Pekarsky B. Sorich MJ, et al. Pharmacogenomics. 2014 Apr;15(6):727-9. doi: 10.2217/pgs.14.24. Pharmacogenomics. 2014. PMID: 24897279 No abstract available.
Cost implications of prehospital emergency drug administration. The case of prehospital thrombolytics.
Barton S, Walley T. Barton S, et al. Pharmacoeconomics. 1996 Nov;10(5):441-52. doi: 10.2165/00019053-199610050-00001. Pharmacoeconomics. 1996. PMID: 10163626 Review. No abstract available.
[When is expensive pharmacotherapy good value for the money?].
Riesberg A, Velasco-Garrido M, Weinbrenner S, Gericke CA, Busse R. Riesberg A, et al. Internist (Berl). 2004 Oct;45(10):1189-95. doi: 10.1007/s00108-004-1238-z. Internist (Berl). 2004. PMID: 15526176 Review. German.
Multi-modal management of acromegaly: a value perspective.
Kimmell KT, Weil RJ, Marko NF. Kimmell KT, et al. Pituitary. 2015 Oct;18(5):658-65. doi: 10.1007/s11102-014-0626-1. Pituitary. 2015. PMID: 25557288

See all similar articles

Cited by

Cost of management of invasive growth hormone-secreting macroadenoma.
Luque-Ramírez M, Paramo C, Varela da Costa C, García-Mayor RV. Luque-Ramírez M, et al. J Endocrinol Invest. 2007 Jul-Aug;30(7):541-5. doi: 10.1007/BF03346346. J Endocrinol Invest. 2007. PMID: 17848835
Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly.
Gillis JC, Noble S, Goa KL. Gillis JC, et al. Drugs. 1997 Apr;53(4):681-99. doi: 10.2165/00003495-199753040-00009. Drugs. 1997. PMID: 9098666 Review.

References

1. Ann Intern Med. 1991 Oct 1;115(7):527-32 - PubMed
1. Clin Endocrinol (Oxf). 1994 Jul;41(1):95-102 - PubMed
1. N Engl J Med. 1990 Apr 5;322(14):966-77 - PubMed
1. Surg Neurol. 1985 May;23(5):513-9 - PubMed
1. J Clin Endocrinol Metab. 1993 Sep;77(3):790-3 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.